Experience and Prognostic Analysis with Avelumab Switch Maintenance Treatment in Metastatic Urothelial Carcinoma
Oncology · 2024
DOI: 10.1159/000539795 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, 2024. Verfasst von Teruki Isobe und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Transitional Cell, Antineoplastic Agents, Immunological, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
Introduction
Avelumab (Ave) is approved for metastatic urothelial carcinoma (mUC) maintenance therapy and prolongs overall survival (OS). We explored trends related to Ave treatment of mUC patients.
Methods
A total of 72 patients with mUC treated with first-line chemotherapy, from January 2019 to November 2022, at our affiliated institutions, were analyzed. We compared clinical parameters and the prognosis of patients treated with Ave (n = 43) because of progression during first-line chemotherapy, with untreated patients (Ave-untreated; n = 29). Among the Ave-treated group, we classified patients showing a complete or partial response or stable disease in their best response to Ave maintenance therapy as Ave-suitable patients; these were retrospectively analyzed. Potential prognostic factors, including the Geriatric Nutritional Risk Index (GNRI) for determining patients suitable for Ave, were evaluated.
Results
The basic clinical parameters of patients when first-line treatment was initiated were not statistically different between the two groups. The Ave-suitable group (median 26.6 months, 95% confidence interval [CI]: 19.4–not reached [NR]) showed significantly longer median OS after first-line treatment than the Ave-untreated group (median 12.0 months, 95% CI: 7.5–NR) with tolerable adverse events. The cut-off values of prognostic factors were set by the receiver operating characteristic curve. Low age and GNRI sustainability were revealed as significant prognostic factors for being Ave-suitable both in univariate and multivariate analysis.
Conclusion
In mUC, Ave maintenance prolonged OS within tolerable safety profiles. GNRI sustainability may be used as a biomarker to predict being Ave-suitable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
- Department of Pharmacy, Nagoya City University Hospital, Nagoya, Japan.
- Department of Experimental Pathology and Tumor Biology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
- Department of Urology, Anjo Kosei Hospital, Anjo, Japan.
- Department of Urology, Konan Kose Hospital, Konan, Japan.
- Department of Urology, Kainan Hospital, Yatomi, Japan.
Zitieren
APA
Isobe, T., Naiki, T., Sugiyama, Y., Naiki-Ito, A., Nagai, T., Etani, T., Iida, K., Noda, Y., Shimizu, N., Aoki, M., Gonda, M., Morikawa, T., Banno, R., Kubota, H., Ando, R., Kawai, N., & Yasui, T. (2024). Experience and Prognostic Analysis with Avelumab Switch Maintenance Treatment in Metastatic Urothelial Carcinoma. Oncology. https://doi.org/10.1159/000539795
Vancouver
Isobe T, Naiki T, Sugiyama Y, Naiki-Ito A, Nagai T, Etani T, et al. Experience and Prognostic Analysis with Avelumab Switch Maintenance Treatment in Metastatic Urothelial Carcinoma. Oncology. 2024. doi:10.1159/000539795
BibTeX
@article{Isobe2024,
author = {Isobe, Teruki and Naiki, Taku and Sugiyama, Yosuke and Naiki-Ito, Aya and Nagai, Takashi and Etani, Toshiki and Iida, Keitaro and Noda, Yusuke and Shimizu, Nobuhiko and Aoki, Maria and Gonda, Masakazu and Morikawa, Toshiharu and Banno, Rika and Kubota, Hiroki and Ando, Ryosuke and Kawai, Noriyasu and Yasui, Takahiro},
title = {Experience and Prognostic Analysis with Avelumab Switch Maintenance Treatment in Metastatic Urothelial Carcinoma},
journal = {Oncology},
year = {2024},
doi = {10.1159/000539795}
}
EUVIMED